Data from EMC - Curated by Toby Galbraith - Last updated 09 August 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Temozolomide Teva is indicated for the treatment of:
- adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.
- children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone


Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

Visit Prostate Cancer


Related Content

More information

Category Value
Agency product number EMEA/H/C/001126
Orphan designation No
Date First Approved 28-01-2010
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Teva B.V.